Id Quantique

Combinostics provides a clinical decision support platform for neurological disorders, acquired by SyntheticMR in January 2025. The company was founded in 2014 in Tampere, Finland, by Lennart Thurfjell, Jyrki Lötjönen, and Jussi Mattila. The founders leveraged their backgrounds in medical imaging and technology to address the challenges of diagnosing neurodegenerative diseases. Thurfjell has extensive experience in medical image processing and has held leadership roles at GE Healthcare. Mattila and Lötjönen both have backgrounds as scientists at the VTT Technical Research Centre of Finland, specializing in biosignal and medical image processing.

The company's core offering is the cNeuro platform, a cloud-based suite of software tools that integrates and analyzes patient data from multiple sources. This includes MRI scans, PET images, lab results like CSF biomarkers, and neuropsychological tests. The platform uses artificial intelligence and patented "disease state fingerprint" technology to compare a patient's data against large databases of previously diagnosed cases, helping clinicians with early detection, differential diagnosis, and prediction of disease progression. Key products within the suite are cMRI, for automated quantification of brain MRI scans, and cDSI, the clinical decision support application that provides a holistic view of the patient's data. The platform is designed to assist in the diagnosis and management of conditions such as Alzheimer's disease, multiple sclerosis, dementia, and traumatic brain injury.

Combinostics operates on a software-as-a-service (SaaS) business model, providing its tools to healthcare professionals, primarily in radiology and neurology departments at memory clinics and hospitals. The service aims to improve diagnostic accuracy, reduce costs associated with follow-up visits, and enable earlier treatment. The company was acquired by the Swedish company SyntheticMR on January 2, 2025, for €4.3 million. Before the acquisition, Combinostics had raised a total of $4.3M over 5 funding rounds from investors including Industrifonden, NordicNinja, and the European Union.

Keywords: neurological disorders, clinical decision support, medical imaging AI, brain MRI quantification, dementia diagnosis, Alzheimer's disease, multiple sclerosis, cNeuro platform, PET neurology, medical image analysis, evidence-based diagnosis, disease state fingerprint, neurodegenerative diseases, quantitative neuroradiology, healthtech, CSF biomarkers, neuropsychological data integration, patient data management, diagnostic software, multimodal data analysis